Bioscape Campus Collapses: 500 Antwerp Jobs Lost

Investors have withdrawn from Bioscape, a planned life-sciences research campus on the University of Antwerp’s Drie Eiken Campus in Edegem, the university confirmed on Monday. The project, which was expected to create roughly 500 high-skilled science jobs, will now not be built — a major setback for the Antwerp region’s ambitions in biotechnology and a flashpoint in Flanders’ long-running debate over permit procedures.

The University of Antwerp (UAntwerpen) said the investors formally notified it of their decision in late September. “The investors have unfortunately now let us know that they are withdrawing from the project and that Bioscape will not be realised,” university spokesperson Peter De Meyer told VRT NWS. “They refer among other things to the deteriorated economic climate and the geopolitical situation in the world.”

What Bioscape Was Meant to Be

Bioscape was conceived as a bio-incubator — a hub where spin-offs, start-ups and growing biotech and pharmaceutical companies could develop in close cooperation with knowledge institutions such as UAntwerpen and care actors such as the Antwerp University Hospital (UZA). Located next to Vaccinopolis, the planned campus comprised three new laboratory buildings: a central community building of 9,987 square metres and two accelerator buildings of 8,600 square metres each, totalling around 28,000 square metres, according to a legal analysis by LexGO.

The developer and building owner is Biovest, which holds the land in long lease (erfpacht) from the university. The project was developed at the request of, and in cooperation with, UAntwerpen.

The campus was to be equipped with laboratories and advanced, expensive equipment that young researchers and start-up companies could otherwise not afford. “They lay the basis, the seed, at the university itself, but must then go to market,” De Meyer said. “Together with partners such as UZA, we therefore wanted to build a so-called biotech ecosystem.”

The Permit That Was Annulled

The project’s environmental permit was granted on 5 September 2025 by the Flemish Government, acting as appeal authority, despite an unfavourable opinion from the Regional Environmental Permit Commission (GOVC) on, among other things, mobility.

A local resident then challenged the permit. On 20 August 2026, the Council for Permit Disputes annulled it. As VRT NWS reported, the Council found that the Flemish Government had not sufficiently examined the project’s impact on mobility. The ruling cited problems with cyclist safety and the flow of car traffic, and noted that the government relied on road works that had not yet been applied for or permitted — let alone carried out.

According to LexGO, the Council held that a mobility assessment must rest on existing and concrete facts that have been carefully established, and that a solution dependent on third parties — such as an existing campus car park about 300 metres away, for which no concrete arrangements had been made — could not be treated as settled. The Flemish Government was given three months to take a new decision on the administrative appeal.

Growing Frustration Over Permits

The withdrawal has reignited a fierce debate about legal certainty and permitting in Flanders. The employers’ organisation Voka Antwerpen-Waasland, which had championed Bioscape as a central project in its “Routeplan 2030,” voiced deep disappointment.

“500 well-paid science jobs would have been created there, but this has dragged on far too long,” said Luc Luwel, managing director of Voka Antwerpen-Waasland. “If one can always appeal, often individually for private interests, it is particularly regrettable that this happens in a period when the economy is doing badly.”

In an earlier stakeholder statement, Voka argued that the system had become unbalanced. “Today, a single appeal by a single local resident is enough to put a socially relevant project, good for around five hundred jobs, in uncertainty for months,” the organisation wrote.

Not everyone agrees. Koenraad Van De Sijpe, the lawyer for the residents, rejected the framing that this was a one-man protest. “We know that Voka is the mouthpiece of enterprising Flanders,” he told Made in Antwerpen. “That does not take away from the fact that one must follow the rules. And here the rules are being stretched.” He said the GOVC had also issued an unfavourable opinion, and that a single resident had taken the lead only to centralise costs.

Edegem’s mayor, Koen Metsu of the N-VA, had strongly backed the project. “Bioscape is a unique opportunity for Edegem to play a pioneering role in the Flemish biotech sector,” he said. “The project creates hundreds of high-quality jobs and uses an extremely suitable location, right next to the university and away from residential areas.”

What’s Next

The university said it will look for new investors, but fears this will be difficult. “What will certainly not happen is that the university will finance such a biotech campus or biotech hub with its own resources. We do not have those resources,” De Meyer said. He warned that promising young researchers may now leave Antwerp — “and perhaps even go abroad” — to develop and bring their medicines and therapies to market.

The decision lands amid a difficult climate for industry in the Antwerp region, where chemicals group BASF Antwerp has announced 600 job cuts and German chemicals group Evonik is also reducing jobs. For Voka, Bioscape has become a test case: “Entrepreneurs seek legal certainty. If procedures drag on for years, ultimately people will stop investing.”

The Flemish Government is still formally due to decide anew on the permit appeal, and Bioscape could in theory be revived by fresh investors. But with the original backers gone and the university unable to self-finance, the flagship life-sciences campus as planned will not be realised — leaving the region to reckon with the wider question of how it balances residents’ rights against strategic investment.